Q&A Ask the Expert | Re-Evaluating Patients with Gleason 8
E. David Crawford, MD asked expert Francisco G. La Rosa, MD, FACS about reporting Gleason grades....
Read More
Ask the Expert
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses what some of the...
Read More
Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising.
Read More
Ask the Expert: Will More Individuals Over Time Be Diagnosed with Prostate Cancer?
Gerald L. Andriole, Jr., MD, Barnes-Jewish Hospital, St. Louis, Missouri, discusses whether over...
Read More
Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?
Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, Connecticut, discusses some of the steps...
Read More
What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses if there...
Read More
Ask the Expert: Which New Biomarkers Can Help Guide Treatment for Prostate Cancer?
Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, Connecticut, discusses which new biomarkers...
Read More
Ask the Expert: Is Photodynamic Therapy Being Combined with Other Therapies?
James A. Eastham, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, discusses...
Read More
Q&A Ask the Expert | UroLift
UroLift can be a good option for patients who are frustrated with urinary symptoms they experience...
Read More
Ask the Expert: What Changes Are Happening in Anti-Androgen Therapy for Prostate Cancer?
Neal D. Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, South Carolina,...
Read More
Ask the Expert: Should Photodynamic Therapy Be Used as a Single or Multi-Pronged Treatment Strategy?
James A. Eastham, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, discusses...
Read More
Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?
Alan W. Partin, MD, Johns Hopkins Medical Institutions, Baltimore, Maryland, discusses which...
Read More